Ionis Pharmaceuticals develops RNA-targeted therapeutics for various indications. They offer existing treatments for spinal muscular atrophy (SMA), hereditary transthyretin amyloidosis, and familial chylomicronemia syndrome. The company also has multiple medicines in phase 3 studies, including treatments for ATTR, hereditary angioedema, amyotrophic lateral sclerosis, cardiovascular disease, and hepatitis B virus.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |